Abstract 3502
Background
Continuing the treatment of tyrosine kinase inhibitors (TKIs) after disease progression (PD) in EGFR-mutation NSCLC was reported promising in several studies, but rare research presented continued ALK-TKIs beyond PD in NSCLC. Thus, we retrospectively analyzed the continuation of crizotinib treatment beyond PD in ALK-positive patients.
Methods
The progression free survival (PFS, time from first crizotinib dose to first RECIST-defined PD), PFS2 (time from continuing crizotinib treatment beyond PD to drug withdrawal or death), overall survival (OS, time from first crizotinib dose to death), objective response rate (ORR) and disease control rate (DCR) were analyzed in this study. Patterns of PD were identified by patients underwent rapid radiographic/clinical disease progression or died within 3 months after PD.
Results
Of 108 patients screened, 53 patients got PD at the cutoff time. Median follow-up was 12.3 months. After PD, 23 patients discontinued crizotinib treatment and 30 patients continued. Baseline characteristics showed that continued ones had a better ECOG performance status than discontinued ones (P = 0.006). Patterns of PD was significantly different in two groups (P
Conclusions
ALK-positive NSCLC may get clinical benefits from the continuation of crizotinib beyond PD, especially in those patients with brain or bone metastases.
Clinical trial identification
-
Legal entity responsible for the study
Department of Thoracic Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Medical School, Sichuan University
Funding
N/A
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract